Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals (NASDAQ: IDRA) today announced that it has initiated dosing in a randomized, double-blind, placebo-controlled Phase 2 trial of IMO-8400 in patients with moderate to severe plaque psoriasis. IMO-8400, an antagonist of the Toll-like receptors (TLRs) 7, 8, and 9, is a lead clinical candidate in Idera’s autoimmune disease program. In a Phase 1 trial involving single escalating doses and multiple doses, IMO-8400 was well tolerated and inhibited TLRs 7, 8, and 9-mediated immune responses. Data from the Phase 1 study will be presented at a scientific meeting in June 2013.
Help employers find you! Check out all the jobs and post your resume.
